We knew this day was.coming. The question will be which current companies simply get bowled over when the big boys enter, which are worth gobbling up. And lastly, which will find a lucrative niche when big Pharma and big Bev/Cannabis start there moves to run the table on both the medical and rec sides. 2022 will be a year of winners and losers, decisively, iMO.